Skip to main content

The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.

Publication ,  Journal Article
Geradts, J; Bean, SM; Bentley, RC; Barry, WT
Published in: Cancer Invest
November 2010

In a series of 177 breast carcinomas, we found that the Oncotype DX Recurrence Score (RS) was correlated with six pathobiologic features: estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status, and the three components of the Nottingham tumor grade. The RS also correlated with a composite index (the Breast Cancer Prognostic Score or BCPS) comprising the same six parameters. Categorical concordance was 56% and 66% using conventional and TAILORx cutoffs, respectively. Our data show that a composite prognostic index can be constructed from routinely reported breast tumor features that captures much of the information provided by the Oncotype assay at no added cost.

Duke Scholars

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

November 2010

Volume

28

Issue

9

Start / End Page

969 / 977

Location

England

Related Subject Headings

  • Severity of Illness Index
  • Receptors, Progesterone
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Multivariate Analysis
  • Logistic Models
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Geradts, J., Bean, S. M., Bentley, R. C., & Barry, W. T. (2010). The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest, 28(9), 969–977. https://doi.org/10.3109/07357907.2010.512600
Geradts, Joseph, Sarah M. Bean, Rex C. Bentley, and William T. Barry. “The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.Cancer Invest 28, no. 9 (November 2010): 969–77. https://doi.org/10.3109/07357907.2010.512600.
Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest. 2010 Nov;28(9):969–77.
Geradts, Joseph, et al. “The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.Cancer Invest, vol. 28, no. 9, Nov. 2010, pp. 969–77. Pubmed, doi:10.3109/07357907.2010.512600.
Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest. 2010 Nov;28(9):969–977.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

November 2010

Volume

28

Issue

9

Start / End Page

969 / 977

Location

England

Related Subject Headings

  • Severity of Illness Index
  • Receptors, Progesterone
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Multivariate Analysis
  • Logistic Models